BioXcel Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
May 10, 2021 07:00 ET
|
BioXcel Therapeutics
Granted FDA Breakthrough Therapy designation for BXCL501 for the acute treatment of agitation associated with dementia; registrational program expected to begin in 2H 2021 Submitted NDA to FDA for...
BioXcel Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences
May 04, 2021 07:00 ET
|
BioXcel Therapeutics
NEW HAVEN, Conn., May 04, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial...
BioXcel Therapeutics to Host First Quarter 2021 Operating and Financial Results Conference Call and Webcast
May 03, 2021 07:00 ET
|
BioXcel Therapeutics
NEW HAVEN, Conn., May 03, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI), a clinical-stage biopharmaceutical company utilizing artificial...
BioXcel Therapeutics Launches “Boiling Point” Educational Campaign to Shed Light on the Importance of Prompt and Cooperative De-escalation in the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar Disorders
April 29, 2021 07:00 ET
|
BioXcel Therapeutics
The Campaign, launching during Mental Health Awareness Month, aims to educate healthcare providers on the various signs, symptoms, and levels of severity associated with agitation Interactive...
BioXcel Therapeutics Announces Presentations on SERENITY I & II at the 2021 American Psychiatric Association Annual Meeting
April 26, 2021 07:00 ET
|
BioXcel Therapeutics
NEW HAVEN, Conn., April 26, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial...
BioXcel Therapeutics Announces Results of Phase 1b/2 Study of BXCL501 for the Treatment of Opioid Withdrawal Symptoms
March 31, 2021 16:01 ET
|
BioXcel Therapeutics
Primary safety endpoint achieved in first study of BXCL501 dosed twice-daily over seven days RELEASE results demonstrated numerically improved retention rates in multiple BXCL501 dose cohorts Data...
BioXcel Therapeutics Receives FDA Breakthrough Therapy Designation for BXCL501 for the Acute Treatment of Agitation Associated with Dementia
March 15, 2021 07:00 ET
|
BioXcel Therapeutics
NEW HAVEN, Conn., March 15, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial...
BioXcel Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
March 11, 2021 07:15 ET
|
BioXcel Therapeutics
New Drug Application (“NDA”) submitted to the U.S. Food and Drug Administration (“FDA”) for BXCL501 for the acute treatment of schizophrenia and bipolar disorder related agitation TRANQUILITY...
BioXcel Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for BXCL501 for the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar Disorders
March 11, 2021 07:00 ET
|
BioXcel Therapeutics
NEW HAVEN, Conn., March 11, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial...
BioXcel Therapeutics to Host Fourth Quarter and Full Year 2020 Operating and Financial Results Conference Call and Webcast
March 04, 2021 07:00 ET
|
BioXcel Therapeutics
NEW HAVEN, Conn., March 04, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial...